title: Cost-effectiveness of cardiovascular prevention programs in Spain.
abstract: Individual programs for prevention of cardiovascular disease include dietary and drug treatment of hypercholesterolemia, hypertension treatment, and smoking cessation therapies. In this study, the cost-effectiveness of available cardiovascular prevention programs was assessed in Spain in terms of net cost per life-year gained (LYG). Cost-effectiveness ratios ranged from US $2,600 to $80,000 per LYG in men and from $4,500 to $230,000 per LYG in women. In men aged 40-59 years, the ranking of increasing cost-effectiveness was: smoking cessation ($2,608-3,738 per LYG); treatment of moderate and severe hypertension ($8,564-38,678 per LYG); treatment of mild hypertension ($11,906-59,840 per LYG); dietary treatment ($16,143-20,158 per LYG); and drug treatment of hypercholesterolemia ($33,850-81,010 per LYG). In women, the ranking list was:smoking cessation ($4,482-5,756 per LYG), treatment of moderate and severe hypertension ($9,585-57,983 per LYG), treatment of mild hypertension ($15,248-86,075 per LYG), dietary treatment ($57,175-62,154 per LYG); and drug treatment of hypercholesterolemia ($104,100-259,150 per LYG).
authors.affiliation: General Direction of Public Health, Barcelona.
authors.forename: P
authors.initials: P
authors.lastname: Plans-Rubió
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D017046:Cost Savings; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs; D006801:Humans; D006937:Hypercholesterolemia / Q000178:diet therapy / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention / Q000191:economics*; D016540:Smoking Cessation / Q000191:economics; D013030:Spain; D013673:Technology Assessment, Biomedical